Houlihan Lokey enters June with a straightforward but uncomfortable setup: a cluster of C-suite sales at the exact top of the recent range, a stock that has since dropped 8.9% over the past month to $139.43, and short interest that has climbed 42% over the same period.
The insider selling is the most striking feature of the past few weeks. On May 15 alone, seven named insiders — including CEO Scott Adelson, the two Co-Chairmen, and the CFO — all sold shares at $150.35, collectively clearing roughly $7.3 million in stock in a single session. Co-Chairman Scott Beiser followed with a further $941,000 sale on May 21. The 90-day net position across insiders totals approximately $8.6 million in net sales across 57,000 shares. These were not isolated filings; the breadth of the May 15 cluster, spanning the CEO, CFO, both Co-Chairmen, and a director, is the kind of coordinated distribution that draws attention. The stock has since fallen more than 7% from those sale prices.
Short positioning has picked up alongside the price weakness, though it remains modest in absolute terms. Short interest hit 3.4% of the free float as of June 2, up from roughly 2.7% a month ago and up nearly 30% on the week. The week-on-week reading is noisy — daily shares dropped 17% on June 2 after a spike on June 1 — so the trend is better read on the monthly timeframe, where the direction is clearly higher. Cost to borrow stays extremely low at 0.39%, and availability is exceptionally loose at nearly 4,700% of short interest, meaning the lending pool is enormous relative to current short demand. There is no squeeze risk here. The short rebuild looks more like cautious hedging against a stock that has repriced lower than a conviction bear thesis.
Options traders tell a strikingly different story. The put/call ratio is near its 52-week low at 0.065, well below its 20-day mean of 0.19. That places the PCR almost a full standard deviation below normal, which is an unusually call-heavy skew for a stock that has fallen nearly 9% over the past month. The divergence is notable: shorts are rebuilding, but options positioning does not reflect defensive hedging. One possible read is that call activity reflects opportunistic buyers betting the pullback is overdone rather than genuine bullish conviction.
The Street broadly agrees the stock has room higher, but has been walking targets down steadily. Keefe, Bruyette & Woods maintained its Outperform but trimmed its target to $172 after the May earnings print. Morgan Stanley cut to $193 in April. Goldman Sachs has pulled its Buy target from $210 to $184 over the past two months. The consensus mean sits at $172.50, implying about 24% upside from current levels — a wide gap that reflects how far the stock has drifted from where analysts had been pricing it earlier this year. The price-to-earnings multiple has compressed to roughly 16x on a trailing basis, down about one full turn over the past 30 days, while price-to-book eased to 3.6x. Factor scores add nuance: the 12-month forward EPS increase ranks in the 82nd percentile, and the dividend score sits at the 98th percentile, suggesting the underlying business metrics are not deteriorating — the market is doing the repricing work.
The next formal test arrives on July 27, when HLI reports its next quarterly results. The May print produced a modest 2.2% one-day gain, reversing the -3% move from May 8, so the earnings reaction function has been inconsistent. Close peers also had a mixed week: EVR and PJT closed up roughly 1% and 2.7% respectively on the week, while PWP fell nearly 15% and PIPR dropped 4.3%. HLI's 7.5% weekly decline sits toward the worse end of that peer range, amplifying the question of whether firm-specific factors — read: the insider selling signal — are doing more work on price than sector dynamics. What to watch before July 27 is whether the short rebuild stalls or accelerates at current levels, and whether the CEO and Co-Chairmen file any offsetting purchases.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
